Sclerotherapy for simple cysts with use of ethanolamine oleate: preliminary experience.
We evaluated the efficacy of ethanolamine oleate (EO) as a sclerosing agent for a symptomatic hepatic or renal cyst. Seven patients with symptomatic hepatic (n = 3) or renal cysts (n = 4) were treated by sclerotherapy with EO. The cyst size in the greater diameter ranged from 6 to 13 cm. The cyst was punctured under ultrasound guidance, and after all of the cyst's content was aspirated, an iodized contrast agent was injected to check the absence of communication between the cyst and biliary tree, urinary tract, or vessels. Then, the solution of ethanolamine oleate-iopamidol mixture (EOI) of 10% of the volume of the cyst's content was injected via catheter. After 30 min, the injected EOI was aspirated completely before catheter removal. A follow-up computed tomography scan was performed at 1 and 3 months after treatment. The volume of the cyst and its reduction rate was calculated. In addition, symptoms and complications were assessed. The volume of the cyst ranged from 64 to 636 ml (mean: 328 ml) before treatment. Three months after treatment, it ranged from 2 to 50 ml (mean: 15ml) and the reduction rate of the cyst's volume was more than 90% on average. Symptoms caused by the cyst disappeared in all cases and no major complication was encountered. Although two patients had a low-grade fever after sclerotherapy, it was easily controlled. It is suggested that the sclerotherapy with EO might be a safe, effective, well-tolerated treatment for symptomatic hepatic or renal cysts.
Yamamoto
Kiyosei
K
Department of Radiology, Nara Medical University, Kashihara, Nara, Japan. rad@naramed-u.ac.jp
Sakaguchi
Hiroshi
H
Anai
Hiroshi
H
Tanaka
Toshihiro
T
Morimoto
Kengo
K
Kichikawa
Kimihiko
K
Uchida
Hideo
H
D000368:Aged; D000369:Aged, 80 and over; D002404:Catheterization / Q000379:methods; D003287:Contrast Media / Q000008:administration & dosage; D003560:Cysts / Q000628:therapy*; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000008:administration & dosage; D007668:Kidney / Q000000981:diagnostic imaging; D008099:Liver / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D012597:Sclerosing Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome; D014463:Ultrasonography
D003287:Contrast Media; D009829:Oleic Acids; D012597:Sclerosing Solutions; D007479:Iopamidol; C033343:ethanolamine oleate